Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 15 of 46 for:    FERRIC SULFATE

A Pilot Study to Assess the Influence of Dietary Organic Acids on Iron Absorption.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01991600
Recruitment Status : Completed
First Posted : November 25, 2013
Last Update Posted : November 25, 2013
Sponsor:
Information provided by (Responsible Party):
dora pereira, Medical Research Council

Brief Summary:
Iron deficiency is the most common micronutrient deficiency in the world today, affecting more than 60% of the global population (www.who.int/nut/ida.htm). The two main strategies for the prevention and treatment of iron deficiency involve fortification of food with iron, or direct supplementation with iron tablets. Simple iron salts (e.g. ferrous sulphate) are well absorbed but at supplemental levels (and potentially at lower levels, as used in food fortificants) can induce free radical activity resulting in gastrointestinal side effects and systematic oxidative stress. As a result, supplementation has poor compliance and improvement in iron status is compromised. Ferric salts are less inclined to produce side effects and although they are relatively well absorbed at fortification levels in food, they are poorly absorbed at the higher supplemental doses. Because certain components of food, such as organic acids, can facilitate ferric iron absorption, we now wish to determine whether dietary organic acids may similarly enable efficient absorption of supplemental ferric iron while preventing the formation of non-transferrin-bound iron (NTBI) which is a proxy for free radical activity. Our strategy is to use an iterative process between in vitro and in vivo experimentation, aimed at identifying the best choice of organic acid and the optimal ratio of iron:organic acid. The study was a cross-over, single-dose comparison against standard-of-care therapy (namely ferrous sulphate) in mildly iron deficient anaemic women. Both the investigational products and the active comparator were administered as a single dose on 2 different occasions, i.e. the investigational products on the first study visit and the active comparator 14 days later on the second study visit.

Condition or disease Intervention/treatment Phase
Iron Deficiency Anaemia Dietary Supplement: ferrous sulphate Dietary Supplement: ferric iron oxide-organic acid (Fe-OA) Early Phase 1

Detailed Description:

The study was a first-in-human iron absorption study of ferric iron oxide-organic acid preparations (Fe-OAs). The study design was cross-over, single-dose, single-blinded comparison against standard-of-care therapy (namely ferrous sulphate) in mildly iron deficient anaemic women. Methyl-cellulose capsules containing single doses of Fe-OAs (60 mg elemental iron equivalent) were given to four subjects per test mixture to determine iron absorption and bioavailability. The study was initially designed in 2 parts (A and B). Part A was an iterative process to determine the best choice of organic acids and the optimal ratio of iron to organic acid that allowed efficient iron absorption, while part B was a comparison of absorption of the two most promising Fe-OA preparations against the standard-of-care therapy (namely ferrous sulphate). Following this iterative-based study we had a candidate Fe-OA preparation that showed nearly equivalent bioavailability to ferrous sulphate and we decided to stop the study at the end of Part A.

On day 1 of the study (Part A), the participants were given one methyl-cellulose capsule containing one of the Fe-OA preparations to be taken on an empty stomach or with a light breakfast consisting of water and 2 slices of white bread with jam. Participants were blinded to which test preparation they received. Serial serum iron levels were obtained at baseline and then 30, 60, 90, 120, 180, 210 and 240 minutes after ingestion of the iron dosage. Fourteen days later the participants returned for the second study visit where they ingested one ferrous sulphate tablet with a light breakfast, and the same visit protocol was followed. Each subject acted as her own control.

The bioavailability of iron from the Fe-OA preparations was determined by measuring erythrocyte incorporation of labelled iron 14 days following a single oral dose. Each Fe-OA preparation was labelled with 2 mg of the stable isotope 58Fe per single dose of the Fe-OA material. Ferrous sulphate was used as a reference for oral iron therapy and to determine individuals who were non-iron absorbers. Non-iron absorbers were defined as those who had no significant net area under the curve (AUC) for serum iron following ferrous sulphate oral ingestion (i.e. this was defined as a serum iron increase ≤ 5 μM). The data obtained for these individuals were excluded from the final analysis.

The bioavailability of ferrous sulphate was determined using short-term changes in serum iron levels using published algorithms.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 71 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: A Pilot Study to Assess the Influence of Dietary Organic Acids on Iron Absorption.
Study Start Date : May 2006
Actual Primary Completion Date : May 2010
Actual Study Completion Date : May 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anemia Iron

Arm Intervention/treatment
Active Comparator: Ferrous Sulphate
The active comparator was the standard-of-care therapy for iron deficiency anaemia (namely ferrous sulphate). Generic uncoated ferrous sulphate tablets BP 300 mg containing 60mg elemental iron were purchased from a local pharmacy. The route of administration was oral. Each participant ingested one ferrous sulphate tablet (60 mg Fe) on one of the study visits.
Dietary Supplement: ferrous sulphate
Experimental: ferric iron oxide-organic acid (Fe-OA)
Fifteen different ferric iron oxide-organic acid preparations were investigated. Most organic acids used were generally recognised as safe (GRAS) and all were used at dietary equivalent levels. The dosage was 58 ± 6 mg elemental iron equivalent (average of all compounds). The route of administration was oral using methyl-cellulose capsules. On one of the study visits, each participant ingested a single dose, equivalent to ca. 60 mg iron, of the Fe-OA preparation allocated to her.
Dietary Supplement: ferric iron oxide-organic acid (Fe-OA)



Primary Outcome Measures :
  1. Iron Bioavailability [ Time Frame: 14 days ]
    The primary outcome was bioavailability of iron from ferric iron oxide-organic acid preparations (Fe-OA) as measured by erythrocyte incorporation of labelled iron (58Fe).


Secondary Outcome Measures :
  1. Iron absorption [ Time Frame: 4 hours ]
    The secondary outcomes were total iron absorption and the rates of iron absorption in the 4 hours following the ingestion of the ferric iron oxide-organic acid preparations (Fe-OA)and the active comparator (namely ferrous sulphate).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Female aged 18-45 years.

Low iron stores based on one of the following criteria:

(I) Mild iron deficiency anaemia defined as haemoglobin between 10-11.9 g/dL plus either a serum ferritin less than 20 μg/L or transferrin saturation < 10% or (II) iron deficiency defined as a serum ferritin less than 12 μg/L.

Exclusion Criteria:

  • pregnancy and lactation
  • surgery in the past three months
  • cancer in last ten years
  • known chronic infection
  • chronic inflammation
  • moderate or severe anaemia
  • known cardiovascular disease
  • chronic respiratory disease.
  • history of hereditary haemochromatosis or haemoglobinopathies
  • current proton pump inhibitor medication
  • blood donation/heavy blood loss in the last 3 months
  • iron supplementation in the past 1 month
  • chronic liver disease
  • renal disease
  • Coeliac Disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01991600


Locations
Layout table for location information
United Kingdom
MRC Human Nutrition Research
Cambridge, Cambridgeshire, United Kingdom, CB1 9NL
Sponsors and Collaborators
Medical Research Council
Investigators
Layout table for investigator information
Study Chair: Jonathan Powell, PhD Medical Research Council

Layout table for additonal information
Responsible Party: dora pereira, Dr, Medical Research Council
ClinicalTrials.gov Identifier: NCT01991600     History of Changes
Other Study ID Numbers: 6129
First Posted: November 25, 2013    Key Record Dates
Last Update Posted: November 25, 2013
Last Verified: November 2013

Keywords provided by dora pereira, Medical Research Council:
iron absorption
bioavailability
anaemia
iron deficiency
ferrous sulphate

Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia, Iron-Deficiency
Anemia
Hematologic Diseases
Anemia, Hypochromic
Iron Metabolism Disorders
Metabolic Diseases
Iron
Trace Elements
Micronutrients
Nutrients
Growth Substances
Physiological Effects of Drugs